Literature DB >> 23712469

Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Vincent Doré1, Victor L Villemagne, Pierrick Bourgeat, Jurgen Fripp, Oscar Acosta, Gael Chetélat, Luping Zhou, Ralph Martins, Kathryn A Ellis, Colin L Masters, David Ames, Oliver Salvado, Christopher C Rowe.   

Abstract

IMPORTANCE: β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition accelerates gray matter atrophy at early stages of the disease even before objective cognitive impairment is manifested. Identification of at-risk individuals at the presymptomatic stage has become a major research interest because it will allow early therapeutic interventions before irreversible synaptic and neuronal loss occur. We aimed to further characterize the cross-sectional and longitudinal relationship between Aβ deposition, gray matter atrophy, and cognitive impairment.
OBJECTIVE: To investigate the topographical relationship of Aβ deposition, gray matter atrophy, and memory impairment in asymptomatic individuals with Alzheimer disease pathology as assessed by Pittsburgh compound B positron emission tomography (PiB-PET).
DESIGN: Regional analysis was performed on the cortical surface to relate cortical thickness to PiB retention and episodic memory.
SETTING: The Australian Imaging, Biomarkers, and Lifestyle Study of Aging, Austin Hospital, Melbourne, Australia. PARTICIPANTS: Ninety-three healthy elderly control subjects (NCs) and 40 patients with Alzheimer disease from the Australian Imaging, Biomarkers, and Lifestyle Study of Aging cohort. INTERVENTION: Participants underwent neuropsychological evaluation as well as magnetic resonance imaging and PiB-PET scans. Fifty-four NCs underwent repeated scans and neuropsychological evaluation 18 and 36 months later. MAIN OUTCOMES AND MEASURES: Correlations between cortical thickness, PiB retention, and episodic memory. RESULTS There was a significant reduction in cortical thickness in the precuneus and hippocampus associated with episodic memory impairment in the NC PiB-positive (NC+) group when compared with the NC- group. Cortical thickness was also correlated negatively with neocortical PiB in the NC+ group. Longitudinal analysis showed a faster rate of gray matter (GM) atrophy in the temporal lobe and the hippocampi of the NC+ group. Over time, GM atrophy became more extensive in the NC+ group, especially in the temporal lobe. CONCLUSIONS AND RELEVANCE: In asymptomatic individuals, Aβ deposition is associated with GM atrophy and memory impairment. The earliest signs of GM atrophy were detected in the hippocampus and the posterior cingulate and precuneus regions, and with disease progression, atrophy became more extensive in the temporal lobes. These findings support the notion that Aβ deposition is not a benign process and that interventions with anti-Aβ therapy at these early stages have a higher chance to be effective.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712469     DOI: 10.1001/jamaneurol.2013.1062

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  78 in total

Review 1.  Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Trends Cogn Sci       Date:  2013-09-09       Impact factor: 20.229

Review 2.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

3.  Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.

Authors:  Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  APOEε4 Genotype and Hypertension Modify 8-year Cortical Thinning: Five Occasion Evidence from the Seattle Longitudinal Study.

Authors:  Philippe Rast; Kristen M Kennedy; Karen M Rodrigue; Paul R A W Robinson; Alden L Gross; Donald G McLaren; Tom Grabowski; K Warner Schaie; Sherry L Willis
Journal:  Cereb Cortex       Date:  2018-06-01       Impact factor: 5.357

Review 5.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 6.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

7.  The transitional association between β-amyloid pathology and regional brain atrophy.

Authors:  Philip S Insel; Niklas Mattsson; Michael C Donohue; R Scott Mackin; Paul S Aisen; Clifford R Jack; Leslie M Shaw; John Q Trojanowski; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

8.  Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Authors:  Ann Hake; Paula T Trzepacz; Shufang Wang; Peng Yu; Michael Case; Helen Hochstetler; Michael M Witte; Elisabeth K Degenhardt; Robert A Dean
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

9.  BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman
Journal:  Brain       Date:  2016-08-12       Impact factor: 13.501

Review 10.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.